Skip to content
Open access

Myeloid-derived MIF is a central regulator of MDSC-driven T-cell dysfunction in head and neck squamous cell carcinoma

Aug 2026 · Oncoimmunology · Vol 15 · 0 citations · 71 references
Medicine

TL;DR

These findings identify myeloid-derived MIF as a central regulator of the MDSC–Treg–CD8⁺ axis in HNSCC and support myeloid-targeted MIF inhibition as a strategy to reprogram the TME and enhance responses to immune checkpoint blockade.

Abstract

Abstract Background Head and neck squamous cell carcinoma (HNSCC) exhibits a profoundly immunosuppressive tumor microenvironment (TME) enriched for myeloid-derived suppressor cells (MDSCs), regulatory T cells (Tregs), and dysfunctional CD8⁺ T cells, limiting therapeutic benefit from immune checkpoint blockade. Macrophage migration inhibitory factor (MIF) is elevated in HNSCC and linked to poor outcomes, yet the cellular source and functional role of tumor-promoting MIF in shaping antitumor immunity remain unclear. Methods We used a myeloid-specific MIF knockout mouse (mMIF KO) in an orthotopic MOC2 HNSCC model and evaluated immune function using ex vivo co-cultures of tumor-derived MDSCs with naïve T cells under Treg-skewing, basal, or Th1-polarizing conditions. Results Myeloid-restricted MIF deletion significantly reduced tumor growth and increased CD8⁺ T cell infiltration, accompanied by reduced CTLA4, TIGIT, and TIM3 expression, with elevated PD1 consistent with antigen-engaged effector activation. High-dimensional immune profiling revealed expansion of cytotoxic CD8⁺ T cell states (GranzymeBhi/Perforinhi) and contraction of IL10–producing CD4⁺ regulatory (Tr1-like) populations, findings corroborated by decreased intratumoral CD4⁺FoxP3⁺Tregs. Within the myeloid compartment, MIF deletion selectively depleted polymorphonuclear MDSCs (PMN-MDSCs), including CSF1Rhi and PD-L1hi subsets. Functionally, tumor-derived MDSCs lacking MIF showed impaired capacity to induce Tregs and to promote CD8⁺ T cell exhaustion in ex vivo co-cultures, effects partially overcome by TGFβ/Th1-polarizing signals. Conclusions These findings identify myeloid-derived MIF as a central regulator of the MDSC–Treg–CD8⁺ axis in HNSCC and support myeloid-targeted MIF inhibition as a strategy to reprogram the TME and enhance responses to immune checkpoint blockade.

Read PDF

Similar papers

Review Open access Aug 2026

Myeloid-derived suppressor cells in laryngeal squamous cell carcinoma: an underexplored immunosuppressive axis and strategic target for overcoming checkpoint inhibitor resistance

It is argued that combining MDSC-targeting strategies with PD-1 blockade merits dedicated clinical investigation in this disease and supported MDSCs as a clinically tractable immunosuppressive node in LSCC.

Guan-Jiang Huang, Xue-Sen Yang, Peijie Li et al. · 1 citation
Open access Sep 2026

Myeloid-derived suppressor cells confer stemness to esophageal cancer cells through the HNF1A/CXCL1 signaling axis

It is shown that MDSCs accelerate ESCC growth in both immunocompetent and T cell-deficient mice, indicating an intrinsic tumor-promoting program and targeting this pathway may complement T cell-focused therapies in ESCC.

Guo-Hui Qin, Ping-Chuan Ma, Sha-Sha Liu et al. · 0 citations
Open access Aug 2026

EphA4 Mediates Pro- and Antitumoral Effects Through Upstream Negative Regulation of AKT in Head and Neck Squamous Cell Carcinoma.

Head and Neck Head and Neck Squamous Cell Carcinoma (HNSCC) is driven by an immunosuppressive tumor microenvironment (TME). We examined the immune-modulatory role of EphA4 in HNSCC using spatial analysis, multi-compartment RNA-sequencing from Oral Cavity Squamous Cell Carcinoma (OCSCC), and three genetically engineered...

S. Corbo, Khalid N. M. Abdelazeem, D. Nguyen et al. · 0 citations
Review Open access Sep 2026

Myeloid-derived suppressor cells in cancer: biology, regulatory networks and theranostic prospects

This review systematically summarizes the classification and identification of myeloid-derived suppressor cells, their biological properties in the context of tumors and autoimmune diseases, genetic and signaling pathway regulatory mechanisms, differentiation skewing in the TME, and cellular interactions with the TME.

Rong-Jun Deng, Xiu-Yun Bai, Jue Yang et al. · 0 citations
Open access Sep 2026

Targeting SHMT2 reverses lactate-driven CAF-mediated T-cell exclusion and sensitizes HNSCC to anti-PD-1 immunotherapy

It is suggested that the SHMT2–lactate–CAF axis contributes to the metabolic–stromal regulation of T-cell exclusion and may represent a potential therapeutic target for improving the response of immune-excluded HNSCC to PD-1 blockade.

He-Lei Yan, Lu Wang, Zhen Li et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.